{"disease":{"id":"corneal-persistent-epithelial-defect","name":"corneal persistent epithelial defect"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04081103","title":"NEXAGON for the Treatment of Corneal Persistent Epithelial Defects Following Severe Ocular Injuries","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":35,"lead_sponsor_name":"Glaukos Corporation","has_results":true}],"total":1},"guidelines":[],"source":"Drug Landscape verified database"}